Samar Farghali Farid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Samar Farghali Farid has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Maggie M. Abbassi
Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
9 shared publications - Ahmed Mohamed Kamel
Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt
7 shared publications - Nirmeen Ahmed Sabry
Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Giza, Egypt
6 shared publications Darrin Baines
Initiate Consultancy, London, UK
4 shared publicationsMaggie Abbassi
Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
4 shared publicationsSahar Al Shabasy
Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-15
Psychometric properties of EQ-5D-Y-3L versus EQ-5D-Y-5L Arabic versions in healthy and diseased children
- 30 September 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-15
Open AccessPsychometric properties of EQ-5D-Y-3L versus EQ-5D-Y-5L Arabic versions in healthy and diseased children
- 28 July 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-20
Psychometric benefits of adding four bolt-ons (skin irritation, self-confidence, social relationships and sleep) to EQ-5D-5L compared to PROMIS-29 and Skindex-16 in patients with psoriasis and atopic dermatitis
- 28 July 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-20
Psychometric benefits of adding four bolt-ons (skin irritation, self-confidence, social relationships and sleep) to EQ-5D-5L compared to PROMIS-29 and Skindex-16 in patients with psoriasis and atopic dermatitis
- Open Access
- 30 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Mapping health-related quality of life measurement tools in Africa: a scoping review
Background: Health-related quality of life (HRQoL) is an important measure in healthcare that captures the multidimensional effects of health on individuals’ lives. While HRQoL measures are widely used globally, there is limited consolidated evidence of their application in Africa. This review aimed to explore and map the available evidence on the utilization of HRQoL measures in Africa, with a focus on understanding their application across diverse populations, health conditions, and geographical regions while identifying gaps, methodological inconsistencies, and opportunities for future research. Methods: The scoping review was conducted following the Arksey and O’Malley framework. Electronic databases, including Medline, Embase, Emcare, CINAHL, and Cochrane Library, and other sources, were searched from the inception up until August 2025. Results were synthesized narratively with descriptive statistics, presented using tables and graphs. Results: Out of 20,438 records identified, 731 studies met the inclusion criteria. The geographical distribution revealed significant disparities, with over half of the studies originating from Nigeria (21.8%), Ethiopia (14.8%), and South Africa (14.5%). Most studies (74.2%) employed descriptive designs and were conducted in hospital settings (70.3%). HRQoL instruments were used across a wide range of health conditions, with HIV/AIDS (20.5%), cancer (10.1%), and diabetes (7.1%) being the most frequently studied. Generic HRQoL tools such as WHOQOL-BREF (19.7%), SF-36 (16.4%), and EQ-5D (13.1%) were the most commonly utilized, accounting for nearly half of all studies. The analysis of information reporting practices for EQ-5D instruments revealed inconsistencies, with only 30.2% of studies reporting all three components (descriptive profile, index scores, and EQ-VAS). Conclusion: This review highlighted the increasing use of HRQoL measures in African health research over the past two decades while identifying significant gaps. Most studies were descriptive, concentrated in a few countries, and primarily conducted in healthcare settings, limiting broader applicability. The frequent use of generic HRQoL instruments underscores their importance and cultural adaptation. Additionally, inconsistencies in reporting practices and methodological limitations hinder the comparability and utility of findings. To advance HRQoL research and its application, it is essential to address these gaps through standardized guidelines, broader geographical representation, and improved methodological rigor.
- 30 May 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessMapping health-related quality of life measurement tools in Africa: a scoping review
Background: Health-related quality of life (HRQoL) is an important measure in healthcare that captures the multidimensional effects of health on individuals’ lives. While HRQoL measures are widely used globally, there is limited consolidated evidence of their application in Africa. This review aimed to explore and map the available evidence on the utilization of HRQoL measures in Africa, with a focus on understanding their application across diverse populations, health conditions, and geographical regions while identifying gaps, methodological inconsistencies, and opportunities for future research. Methods: The scoping review was conducted following the Arksey and O’Malley framework. Electronic databases, including Medline, Embase, Emcare, CINAHL, and Cochrane Library, and other sources, were searched from the inception up until August 2025. Results were synthesized narratively with descriptive statistics, presented using tables and graphs. Results: Out of 20,438 records identified, 731 studies met the inclusion criteria. The geographical distribution revealed significant disparities, with over half of the studies originating from Nigeria (21.8%), Ethiopia (14.8%), and South Africa (14.5%). Most studies (74.2%) employed descriptive designs and were conducted in hospital settings (70.3%). HRQoL instruments were used across a wide range of health conditions, with HIV/AIDS (20.5%), cancer (10.1%), and diabetes (7.1%) being the most frequently studied. Generic HRQoL tools such as WHOQOL-BREF (19.7%), SF-36 (16.4%), and EQ-5D (13.1%) were the most commonly utilized, accounting for nearly half of all studies. The analysis of information reporting practices for EQ-5D instruments revealed inconsistencies, with only 30.2% of studies reporting all three components (descriptive profile, index scores, and EQ-VAS). Conclusion: This review highlighted the increasing use of HRQoL measures in African health research over the past two decades while identifying significant gaps. Most studies were descriptive, concentrated in a few countries, and primarily conducted in healthcare settings, limiting broader applicability. The frequent use of generic HRQoL instruments underscores their importance and cultural adaptation. Additionally, inconsistencies in reporting practices and methodological limitations hinder the comparability and utility of findings. To advance HRQoL research and its application, it is essential to address these gaps through standardized guidelines, broader geographical representation, and improved methodological rigor.
- 7 April 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (5) , e70142
Beyond Monotherapy: The Superior Efficacy of Combined GLP ‐1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta‐Analysis
Diabetic kidney disease (DKD) is a leading cause of chronic and end‐stage renal diseases. Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) confer renoprotection; however, emerging evidence suggests that combination therapy has synergistic benefits. This meta‐analysis evaluated dual versus monotherapy, focusing on the urinary albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted. PubMed, Scopus, Embase, CINAHL, Medline, and Web of Science were searched until August 2025 for RCTs comparing GLP‐1RA plus SGLT2i versus monotherapy or placebo in adults with T2D. The primary outcome was the change in UACR, and the secondary outcome was eGFR. Pooled standardized mean differences (SMD) were estimated using random‐effects models, including subgroup and sensitivity analyses. Eight RCTs ( n = 1974; sample size, 41–4000; follow‐up, 16 weeks–3.4 years) were included. Combination therapy was well tolerated and significantly reduced UACR compared with monotherapy (SMD –0.25, 95% confidence interval (CI) –0.38, −0.13; I 2 = 0%). The benefits remained significant against SGLT2i alone (SMD, −0.28) but not for GLP‐1RA alone. For eGFR, dual therapy provided a modest benefit versus SGLT2i (SMD 0.12, 95% CI 0.00–0.23) but not for GLP‐1RA. The effects were consistent in patients with DKD and in larger trials. Early SGLT2is and GLP‐1RA combination therapy is safe and provides superior renoprotection compared to monotherapy in patients with type 2 diabetes, albuminuria, and high cardiorenal risk. Broader adoption of combination therapy could improve outcomes, although cost and access barriers remain an issue.
- 7 April 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (5) , e70142
Beyond Monotherapy: The Superior Efficacy of Combined GLP ‐1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta‐Analysis
Diabetic kidney disease (DKD) is a leading cause of chronic and end‐stage renal diseases. Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) confer renoprotection; however, emerging evidence suggests that combination therapy has synergistic benefits. This meta‐analysis evaluated dual versus monotherapy, focusing on the urinary albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted. PubMed, Scopus, Embase, CINAHL, Medline, and Web of Science were searched until August 2025 for RCTs comparing GLP‐1RA plus SGLT2i versus monotherapy or placebo in adults with T2D. The primary outcome was the change in UACR, and the secondary outcome was eGFR. Pooled standardized mean differences (SMD) were estimated using random‐effects models, including subgroup and sensitivity analyses. Eight RCTs ( n = 1974; sample size, 41–4000; follow‐up, 16 weeks–3.4 years) were included. Combination therapy was well tolerated and significantly reduced UACR compared with monotherapy (SMD –0.25, 95% confidence interval (CI) –0.38, −0.13; I 2 = 0%). The benefits remained significant against SGLT2i alone (SMD, −0.28) but not for GLP‐1RA alone. For eGFR, dual therapy provided a modest benefit versus SGLT2i (SMD 0.12, 95% CI 0.00–0.23) but not for GLP‐1RA. The effects were consistent in patients with DKD and in larger trials. Early SGLT2is and GLP‐1RA combination therapy is safe and provides superior renoprotection compared to monotherapy in patients with type 2 diabetes, albuminuria, and high cardiorenal risk. Broader adoption of combination therapy could improve outcomes, although cost and access barriers remain an issue.
- Open Access
- 12 February 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Translation and cultural adaptation of the EQ-5D-Y-5L into Modern Standard Arabic for use in Egypt
Background: The use of the EQ-5D-Y-5L to evaluate children and adolescents’ health-related quality of life (HRQOL) is an essential contribution to economic evaluation methods. Accurate translation and cultural adaptation of questionnaires are crucial for their effective use, enabling comparison of data across different languages. Therefore, this study aimed to translate and culturally adapt the EQ-5D-Y-5L into Standard Arabic for use in Egypt. Methodology: The translation process was done according to the methodology and translation guidelines approved by the EuroQol Group Version Management Committee. Two forward translations into Arabic, then two back translations to English were performed, independently. The third step was conducting cognitive interviews with the children, which included a card-ranking exercise, self-completion of the translated Arabic questionnaire, and detailed discussion with the children about the questionnaire sentences. The last step was proofreading of the final Arabic version of the questionnaire. Results: The first Arabic versions of the paper and digital questionnaires were created after the forward translation. Following the back translation, only one modification was made in the digital source of the Arabic version. Cognitive interviews were conducted with 11 children with a mean age of 10.6 years. Some changes were suggested based on the initial 8 interviews in the Pain or Discomfort dimension and in the visual analogue scale (VAS) instructions. Three additional interviews were carried out to discuss these changes, and all were accepted. The final Arabic version was then developed after proofreading. Conclusions: The Standard Arabic version of the EQ-5D-Y-5L produced in this study is an acceptable version that can be used in Egypt and other Arabic-speaking countries.
- 12 February 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessTranslation and cultural adaptation of the EQ-5D-Y-5L into Modern Standard Arabic for use in Egypt
Background: The use of the EQ-5D-Y-5L to evaluate children and adolescents’ health-related quality of life (HRQOL) is an essential contribution to economic evaluation methods. Accurate translation and cultural adaptation of questionnaires are crucial for their effective use, enabling comparison of data across different languages. Therefore, this study aimed to translate and culturally adapt the EQ-5D-Y-5L into Standard Arabic for use in Egypt. Methodology: The translation process was done according to the methodology and translation guidelines approved by the EuroQol Group Version Management Committee. Two forward translations into Arabic, then two back translations to English were performed, independently. The third step was conducting cognitive interviews with the children, which included a card-ranking exercise, self-completion of the translated Arabic questionnaire, and detailed discussion with the children about the questionnaire sentences. The last step was proofreading of the final Arabic version of the questionnaire. Results: The first Arabic versions of the paper and digital questionnaires were created after the forward translation. Following the back translation, only one modification was made in the digital source of the Arabic version. Cognitive interviews were conducted with 11 children with a mean age of 10.6 years. Some changes were suggested based on the initial 8 interviews in the Pain or Discomfort dimension and in the visual analogue scale (VAS) instructions. Three additional interviews were carried out to discuss these changes, and all were accepted. The final Arabic version was then developed after proofreading. Conclusions: The Standard Arabic version of the EQ-5D-Y-5L produced in this study is an acceptable version that can be used in Egypt and other Arabic-speaking countries.
- Open Access
- 7 January 2026
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (3) , 299-306
The impact of intermittent fasting during weight reduction in people living with type 2 diabetes mellitus: a randomized clinical trial
Objectives: Intermittent fasting (IF) has gained attention for weight management and metabolic health, but detailed trials comparing its efficacy to calorie restriction (CR) in type 2 diabetes mellitus (T2D) are limited. Our aim was to compare the impact of CR diet with or without 12-hour overnight IF regimen on weight loss, glycemic control, and reduction of medication use in T2D. Methods: This was a 3-month, single-center randomized clinical trial. Participants (N = 99), 21-60 years with T2D, were randomly assigned to Group 1 (12-hour IF + CR, N = 48) or Group 2 (CR alone, N = 51). Anthropometric evaluations included weight, height, waist and hip circumference, and BMI. Body composition analysis was performed, and biochemical analysis included HbA1c, FBG, and fasting insulin levels to calculate the HOMA-IR. Physical activity was assessed using the Global Physical Activity Questionnaire. Results: Both groups experienced significant weight loss after 12 weeks. The IF + CR group showed a more pronounced weight reduction (-6.51%) compared to the CR group (-4.41%) (P < 0.001) and significant improvements in HbA1c levels, with a reduction to 6.51% compared to 6.86% in the CR group (P = 0.035). The absolute reduction in HbA1c showed a significantly greater median decrease in the IF + CR group [−0.50 (IQR − 0.60 to −0.35)] compared with the CR group [−0.20 (IQR − 0.40 to −0.10)] (P = 0.002). IF + CR demonstrated significant reductions in waist circumference (-4.64%) and hip circumference (-3.12%) compared to the CR (-2.70% and -0.86%, respectively) (P < 0.05). Furthermore, IF + CR showed greater reductions in body fat mass (-9.39%) compared to the CR (-5.32%) (P < 0.001). Physical activity levels were comparable, with average MET of 100 and sedentary hours of 15.7 ( ± 3) for IF + CR and 16.2 ( ± 2.3) for CR, (P = 0.134). Conclusions: A 12-hour intermittent fasting (IF) regimen combined with calorie restriction (CR) demonstrated superior efficacy in promoting weight loss and improving glycemic control in patients with type 2 diabetes (T2D) compared to CR alone. Integrating IF into clinical nutrition guidelines could offer a practical and effective approach to diabetes management. Clinical trial registration: The study was registered at the Pan African Clinical Trial Registry (PACTR202411524439559).
- 7 January 2026
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 80 (3) , 299-306
Open AccessThe impact of intermittent fasting during weight reduction in people living with type 2 diabetes mellitus: a randomized clinical trial
Objectives: Intermittent fasting (IF) has gained attention for weight management and metabolic health, but detailed trials comparing its efficacy to calorie restriction (CR) in type 2 diabetes mellitus (T2D) are limited. Our aim was to compare the impact of CR diet with or without 12-hour overnight IF regimen on weight loss, glycemic control, and reduction of medication use in T2D. Methods: This was a 3-month, single-center randomized clinical trial. Participants (N = 99), 21-60 years with T2D, were randomly assigned to Group 1 (12-hour IF + CR, N = 48) or Group 2 (CR alone, N = 51). Anthropometric evaluations included weight, height, waist and hip circumference, and BMI. Body composition analysis was performed, and biochemical analysis included HbA1c, FBG, and fasting insulin levels to calculate the HOMA-IR. Physical activity was assessed using the Global Physical Activity Questionnaire. Results: Both groups experienced significant weight loss after 12 weeks. The IF + CR group showed a more pronounced weight reduction (-6.51%) compared to the CR group (-4.41%) (P < 0.001) and significant improvements in HbA1c levels, with a reduction to 6.51% compared to 6.86% in the CR group (P = 0.035). The absolute reduction in HbA1c showed a significantly greater median decrease in the IF + CR group [−0.50 (IQR − 0.60 to −0.35)] compared with the CR group [−0.20 (IQR − 0.40 to −0.10)] (P = 0.002). IF + CR demonstrated significant reductions in waist circumference (-4.64%) and hip circumference (-3.12%) compared to the CR (-2.70% and -0.86%, respectively) (P < 0.05). Furthermore, IF + CR showed greater reductions in body fat mass (-9.39%) compared to the CR (-5.32%) (P < 0.001). Physical activity levels were comparable, with average MET of 100 and sedentary hours of 15.7 ( ± 3) for IF + CR and 16.2 ( ± 2.3) for CR, (P = 0.134). Conclusions: A 12-hour intermittent fasting (IF) regimen combined with calorie restriction (CR) demonstrated superior efficacy in promoting weight loss and improving glycemic control in patients with type 2 diabetes (T2D) compared to CR alone. Integrating IF into clinical nutrition guidelines could offer a practical and effective approach to diabetes management. Clinical trial registration: The study was registered at the Pan African Clinical Trial Registry (PACTR202411524439559).
- 1 October 2025
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 44 (6) , 101631
The application of continuous nefopam infusion in analgesia and sedation for mechanically ventilated patients in the ICU: Authors' reply
- 1 October 2025
- Published by Elsevier in Anaesthesia Critical Care & Pain Medicine
- Vol. 44 (6) , 101631
The application of continuous nefopam infusion in analgesia and sedation for mechanically ventilated patients in the ICU: Authors' reply
- 21 August 2025
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (1) , 348-359.e1
Efficacy of Topical Betamethasone Valerate and Olive Oil in Preventing Acute Radiation Dermatitis in Breast Cancer: A Randomized Double-Blind Placebo-Controlled Study
- 21 August 2025
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (1) , 348-359.e1
Efficacy of Topical Betamethasone Valerate and Olive Oil in Preventing Acute Radiation Dermatitis in Breast Cancer: A Randomized Double-Blind Placebo-Controlled Study
- Open Access
- 30 May 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-10
Impact of pharmacist led mobile application on medication adherence and efficacy in chronic kidney disease
Medication adherence is crucial for slowing chronic kidney disease (CKD) progression. A specially designed pharmacist-led mobile application, Kidney Health, was evaluated in a single-center, prospective, 3 months, randomized controlled trial (RCT) to assess its impact on medication adherence and efficacy in patients with CKD. 86 patients were randomly assigned to control group, who received standard of care, and app group, who in addition, had access to Kidney Health. The primary outcome was medication adherence measured by simplified medication adherence questionnaire (SMAQ). Other outcomes evaluated included kidney function, blood pressure, and random blood glucose (RBG). The app group showed a significant increase in adherent patients (P < 0.001) and decreased RBG (P = 0.047). Adherent patients increased (P = 0.002) and RBG decreased (P = 0.006) in app group compared to control group at the end of the study. Kidney Health has shown potential for encouraging patients with CKD to adhere to their medication and improving their clinical outcomes. Trial registration: clinicaltrials.gov with ID: NCT05168449, Date of registration: 12/2021 https://clinicaltrials.gov/study/NCT05168449.
- 30 May 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1) , 1-10
Open AccessImpact of pharmacist led mobile application on medication adherence and efficacy in chronic kidney disease
Medication adherence is crucial for slowing chronic kidney disease (CKD) progression. A specially designed pharmacist-led mobile application, Kidney Health, was evaluated in a single-center, prospective, 3 months, randomized controlled trial (RCT) to assess its impact on medication adherence and efficacy in patients with CKD. 86 patients were randomly assigned to control group, who received standard of care, and app group, who in addition, had access to Kidney Health. The primary outcome was medication adherence measured by simplified medication adherence questionnaire (SMAQ). Other outcomes evaluated included kidney function, blood pressure, and random blood glucose (RBG). The app group showed a significant increase in adherent patients (P < 0.001) and decreased RBG (P = 0.047). Adherent patients increased (P = 0.002) and RBG decreased (P = 0.006) in app group compared to control group at the end of the study. Kidney Health has shown potential for encouraging patients with CKD to adhere to their medication and improving their clinical outcomes. Trial registration: clinicaltrials.gov with ID: NCT05168449, Date of registration: 12/2021 https://clinicaltrials.gov/study/NCT05168449.
- 3 May 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (11) , 3611-3624
The nephroprotective effect of metformin with cisplatin in bladder cancer: randomized clinical trial
Purpose Cisplatin-based combination chemotherapy is the mainstay treatment strategy in various forms of carcinomas and sarcomas. However, its dosage and therapeutic efficacy are significantly limited by its nephrotoxicity. Based on metformin renal benefits in different studies, the study aims to determine safety and the potential nephroprotective effect of metformin when used with cisplatin in patients with bladder cancer. Methods This was a prospective, randomized, parallel, controlled, open-label study in which 78 chemotherapy naïve bladder cancer patients aged 18–65 years and would receive gemcitabine/cisplatin regimen were selected and randomly assigned to treatment or control group in 1:1 allocation. Both groups were receiving cisplatin standard-of-care regimen, whereas metformin (500 mg, twice daily) was added to the treatment group's regimen only. Patients were prospectively followed up for four cycles of gemcitabine/cisplatin with assessment of renal function tests, serum neutrophil gelatinase-associated lipocalin (NGAL), cystatin-c, and metformin's adverse effects. Results Serum creatinine, serum NGAL, and cystatin-C significantly increased in the control group only (P < 0.001). Estimated glomerular filtration rate (eGFR) significantly declines in the control group only (P < 0.001). On the contrary, serum NGAL significantly improved in the treatment group (P = 0.02) with stable and normal mean value of serum creatinine, eGFR, and cystatin-C without a concomitant significant increase in adverse events, such as hypoglycemia, gastrointestinal symptoms, or weight loss compared to the control group. Conclusion Metformin prevented renal damage and deterioration in kidney function in cisplatin-treated patients. Therefore, it is a promising agent in reducing cisplatin-induced nephrotoxicity. The study was registered in ClinicalTrials.gov on December, 16, 2023, Identifier Number NCT06215976.
- 3 May 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (11) , 3611-3624
The nephroprotective effect of metformin with cisplatin in bladder cancer: randomized clinical trial
Purpose Cisplatin-based combination chemotherapy is the mainstay treatment strategy in various forms of carcinomas and sarcomas. However, its dosage and therapeutic efficacy are significantly limited by its nephrotoxicity. Based on metformin renal benefits in different studies, the study aims to determine safety and the potential nephroprotective effect of metformin when used with cisplatin in patients with bladder cancer. Methods This was a prospective, randomized, parallel, controlled, open-label study in which 78 chemotherapy naïve bladder cancer patients aged 18–65 years and would receive gemcitabine/cisplatin regimen were selected and randomly assigned to treatment or control group in 1:1 allocation. Both groups were receiving cisplatin standard-of-care regimen, whereas metformin (500 mg, twice daily) was added to the treatment group's regimen only. Patients were prospectively followed up for four cycles of gemcitabine/cisplatin with assessment of renal function tests, serum neutrophil gelatinase-associated lipocalin (NGAL), cystatin-c, and metformin's adverse effects. Results Serum creatinine, serum NGAL, and cystatin-C significantly increased in the control group only (P < 0.001). Estimated glomerular filtration rate (eGFR) significantly declines in the control group only (P < 0.001). On the contrary, serum NGAL significantly improved in the treatment group (P = 0.02) with stable and normal mean value of serum creatinine, eGFR, and cystatin-C without a concomitant significant increase in adverse events, such as hypoglycemia, gastrointestinal symptoms, or weight loss compared to the control group. Conclusion Metformin prevented renal damage and deterioration in kidney function in cisplatin-treated patients. Therefore, it is a promising agent in reducing cisplatin-induced nephrotoxicity. The study was registered in ClinicalTrials.gov on December, 16, 2023, Identifier Number NCT06215976.